Skip to main content

Table 3 Drug therapy according to neprilysin levels, at baseline and at follow-up

From: Serum neprilysin levels are associated with myocardial stunning after ST-elevation myocardial infarction

  Overall (n = 68) Neprilysin level ≤ 125 pg/mL (n = 38) Neprilysin level 126–450 pg/mL (n = 15) Neprilysin level > 450 pg/mL (n = 15) Overall p.value Highest-level vs. lower groups p.value
At baseline
 antiplatelet agent 6 (8.8%) 2 (5.3%) 1 (6.7%) 3 (20.0%) 0.23 0.23
 beta-blocker 3 (4.4%) 2 (5.3%) 0 1 (6.7%) 0.63 1
 ACEI/ARB/MRA 18 (26.5%) 8 (21.1%) 5 (33.3%) 5 (33.3%) 0.53 0.73
 statins 17 (25.0%) 9 (23.7%) 4 (26.7%) 4 (26.7%) 0.97 1
 diuretics 7 (10.3%) 3 (7.9%) 2 (13.3%) 2 (13.3%) 0.77 1
At follow-up
 antiplatelet agent 68 (100.0%) 38 (100.0%) 15 (100.0%) 15 (100.0)%  
 beta-blocker 64 (94.1%) 36 (94.7%) 14 (93.3%) 14 (93.3%) 0.98 1
 ACEI/ARB/MRA 52 (76.5%) 30 (78.9%) 12 (80.0%) 10 (66.7%) 0.60 0.51
 statins 65 (95.6%) 37 (97.4%) 15 (100.0%) 13 (86.7%) 0.15 0.24
 diuretics 11 (16.2%) 7 (18.4%) 2 (13.3%) 2 (13.3%) 0.86 1